Spruce Street Capital LP Invests $6.15 Million in Enanta Pharmaceuticals, Inc. $ENTA

Spruce Street Capital LP bought a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the 4th quarter, Holdings Channel reports. The institutional investor bought 389,687 shares of the biotechnology company’s stock, valued at approximately $6,145,000. Enanta Pharmaceuticals comprises approximately 2.0% of Spruce Street Capital LP’s holdings, making the stock its 20th largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Deutsche Bank AG increased its position in Enanta Pharmaceuticals by 4.6% during the fourth quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock worth $380,000 after buying an additional 1,055 shares during the period. Public Employees Retirement System of Ohio increased its position in Enanta Pharmaceuticals by 8.3% during the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after buying an additional 1,100 shares during the period. Ameriprise Financial Inc. increased its position in Enanta Pharmaceuticals by 8.3% during the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after buying an additional 1,383 shares during the period. Russell Investments Group Ltd. increased its position in Enanta Pharmaceuticals by 13.4% during the third quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock worth $197,000 after buying an additional 1,940 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on ENTA. Wall Street Zen downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Finally, Rodman & Renshaw began coverage on Enanta Pharmaceuticals in a report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.29.

Enanta Pharmaceuticals Trading Down 3.9%

Enanta Pharmaceuticals stock opened at $11.44 on Tuesday. The firm has a market capitalization of $332.68 million, a P/E ratio of -4.42 and a beta of 0.97. The stock has a fifty day moving average price of $13.41 and a 200 day moving average price of $13.70. Enanta Pharmaceuticals, Inc. has a 52 week low of $6.43 and a 52 week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.01. The firm had revenue of $17.16 million during the quarter, compared to analyst estimates of $17.03 million. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%. As a group, equities analysts predict that Enanta Pharmaceuticals, Inc. will post -1.79 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.